Related Experiment Videos
Botulinum toxin type A for Frey's syndrome: a preliminary prospective study
O Laccourreye1, L Muscatelo, C Naude
1Department of Otorhinolaryngology-Head and Neck Surgery, Laënnec Hospital, Assistance Publique des Hôpitaux de Paris, University Paris V, France.
The Annals of Otology, Rhinology, and Laryngology
|January 24, 1998
Summary
Intracutaneous botulinum toxin type A injections effectively treated severe Frey's syndrome after parotidectomy. This method showed no complications and only temporary adverse effects, offering a promising treatment option.
Area of Science:
- Otolaryngology
- Neurology
- Dermatology
Background:
- Frey's syndrome is a common complication following parotid surgery.
- Existing treatments for Frey's syndrome can be invasive or have limited efficacy.
Purpose of the Study:
- To evaluate the effectiveness and safety of intracutaneous botulinum toxin type A injections for severe Frey's syndrome.
- To assess complications and adverse effects associated with this treatment.
Main Methods:
- Prospective evaluation of fourteen patients with severe Frey's syndrome post-parotidectomy.
- Management involved intracutaneous injections of botulinum toxin type A.
- Analysis of treatment effectiveness, complications, and adverse events.
Main Results:
- Frey's syndrome was consistently controlled within 2 days post-injection.
- No complications were encountered during the study.
- A temporary, slight partial upper lip paresis occurred in 2 patients, resolving within 3 months.
- No recurrence of Frey's syndrome was observed during a 3-9 month follow-up period.
Conclusions:
- Intracutaneous botulinum toxin type A is a valuable and safe treatment for Frey's syndrome after conservative parotidectomy.
- Further investigation into this therapeutic approach is warranted.